These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 36608777)

  • 1. Si-Ni-San reduces lipid droplet deposition associated with decreased YAP1 in metabolic dysfunction-associated fatty liver disease.
    Zheng K; Zhou W; Ji J; Xue Y; Liu Y; Li C; Zhang Z; Lu J; Shi X; Li Y
    J Ethnopharmacol; 2023 Apr; 305():116081. PubMed ID: 36608777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Si-Ni-San Reduces Hepatic Lipid Deposition in Rats with Metabolic Associated Fatty Liver Disease by AMPK/SIRT1 Pathway.
    Zhang N; Liu T; Wang J; Xiao Y; Zhang Y; Dai J; Ma Z; Ma D
    Drug Des Devel Ther; 2023; 17():3047-3060. PubMed ID: 37808345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dihydroartemisinin reduced lipid droplet deposition by YAP1 to promote the anti-PD-1 effect in hepatocellular carcinoma.
    Hao L; Guo Y; Peng Q; Zhang Z; Ji J; Liu Y; Xue Y; Li C; Zheng K; Shi X
    Phytomedicine; 2022 Feb; 96():153913. PubMed ID: 35026515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Si-Ni-San inhibits hepatic Fasn expression and lipid accumulation in MAFLD mice through AMPK/p300/SREBP-1c axis.
    Lan T; Geng XJ; Zhang SJ; Zeng XX; Ying JJ; Xu Y; Liu SY; Li P; Tong YH; Wang W; Mao ZJ; Wang SW
    Phytomedicine; 2024 Jan; 123():155209. PubMed ID: 37984123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated Action of Autophagy and Adipose Tissue Triglyceride Lipase Ameliorates Diet-Induced Hepatic Steatosis in Liver-Specific PLIN2 Knockout Mice.
    Griffin JD; Bejarano E; Wang XD; Greenberg AS
    Cells; 2021 Apr; 10(5):. PubMed ID: 33923083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of Erchen Decoction on liver mitochondrial function by inhibiting mTORC1/SREBP1/CAV1 pathway in mice with high-fat diet].
    Ding SS; Zhuang Y; Liao Y; Kang J; Zhang LY; Shen JY; Liao LH
    Zhongguo Zhong Yao Za Zhi; 2024 Feb; 49(3):763-769. PubMed ID: 38621880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antrodia cinnamomea and its compound dehydroeburicoic acid attenuate nonalcoholic fatty liver disease by upregulating ALDH2 activity.
    Cao YN; Yue SS; Wang AY; Xu L; Hu YT; Qiao X; Wu TY; Ye M; Wu YC; Qi R
    J Ethnopharmacol; 2022 Jun; 292():115146. PubMed ID: 35304272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-122 Inhibits Lipid Droplet Formation and Hepatic Triglyceride Accumulation via Yin Yang 1.
    Wu GY; Rui C; Chen JQ; Sho E; Zhan SS; Yuan XW; Ding YT
    Cell Physiol Biochem; 2017; 44(4):1651-1664. PubMed ID: 29216638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceramide synthase 6 (CerS6) is upregulated in alcohol-associated liver disease and exhibits sex-based differences in the regulation of energy homeostasis and lipid droplet accumulation.
    Jeon S; Scorletti E; Dempsey J; Buyco D; Lin C; Saiman Y; Bayen S; Harkin J; Martin J; Hooks R; Ogretmen B; Argemi J; Melo L; Bataller R; Carr RM
    Mol Metab; 2023 Dec; 78():101804. PubMed ID: 37714377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Liraglutide protects against nonalcoholic fatty liver disease in ApoE knockout mice with high-fat diet and silenced Acrp30 by increasing AMPK].
    Zhao XY; Zhang LL; Suolang QZ; Yang GY; Li L; Li SB; Chen WW
    Zhonghua Gan Zang Bing Za Zhi; 2014 Nov; 22(11):849-53. PubMed ID: 25531383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating network analysis and pharmacokinetics to investigate the mechanisms of Danzhi Tiaozhi Decoction in metabolic-associated fatty liver disease (MAFLD).
    Jiang X; Tang N; Liu Y; Wang Z; Chen J; Liu F; Zhang P; Sui M; Xu W
    J Ethnopharmacol; 2024 Jan; 318(Pt B):117008. PubMed ID: 37549861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dihydroartemisinin ameliorates the liver steatosis in metabolic associated fatty liver disease mice by attenuating the inflammation and oxidative stress and promoting autophagy.
    Hu Y; Peng X; Du G; Zhai Y; Xiong X; Luo X
    Acta Cir Bras; 2023; 38():e385023. PubMed ID: 37851788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dihydroartemisinin modulated arachidonic acid metabolism and mitigated liver inflammation by inhibiting the activation of 5-LOX and COX-2.
    Xue Y; Lu J; Liu Y; Gao Y; Gong Y; Yang Y; Xiong Y; Shi X
    Heliyon; 2024 Jul; 10(13):e33370. PubMed ID: 39027511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A missense variant in human perilipin 2 (
    Scorletti E; Saiman Y; Jeon S; Schneider CV; Buyco DG; Lin C; Himes BE; Mesaros CA; Vujkovic M; Creasy KT; Furth EE; Billheimer JT; Hand NJ; Kaplan DE; Chang KM; Tsao PS; Lynch JA; Dempsey JL; Harkin J; Bayen S; Conlon D; Guerraty M; Phillips MC; Rader DJ; Carr RM
    JHEP Rep; 2024 Jan; 6(1):100902. PubMed ID: 38074507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [METTL3 inhibitor STM2457 improves metabolic dysfunction-associated fatty liver disease by regulating mitochondrial function in mice].
    Gao Y; Wang P; Lu S; Ma W
    Nan Fang Yi Ke Da Xue Xue Bao; 2023 Oct; 43(10):1689-1696. PubMed ID: 37933644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of celastrol on autophagy and endoplasmic reticulum stress-mediated apoptosis in a mouse model of nonalcoholic fatty liver disease].
    Tian T; Liao XC; Zhang M; Wu XM; Guo YT; Tan SY
    Zhonghua Gan Zang Bing Za Zhi; 2022 Jun; 30(6):656-662. PubMed ID: 36038329
    [No Abstract]   [Full Text] [Related]  

  • 17. Olanzapine causes non-alcoholic fatty liver disease via inhibiting the secretion of apolipoprotein A5.
    Li R; Zhu W; Huang P; Ding C; Tang Y; Lian P; Huang X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Jun; 47(6):730-738. PubMed ID: 35837772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Freeze-dried Si-Ni-San powder can ameliorate high fat diet-induced non-alcoholic fatty liver disease.
    Zhu F; Li YM; Feng TT; Wu Y; Zhang HX; Jin GY; Liu JP
    World J Gastroenterol; 2019 Jun; 25(24):3056-3068. PubMed ID: 31293341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomics of lipid-laden human hepatocyte cultures enables drug target screening for the treatment of non-alcoholic fatty liver disease.
    Breher-Esch S; Sahini N; Trincone A; Wallstab C; Borlak J
    BMC Med Genomics; 2018 Dec; 11(1):111. PubMed ID: 30547786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sini San ameliorates CCl4-induced liver fibrosis in mice by inhibiting AKT-mediated hepatocyte apoptosis.
    Jiang M; Huang C; Wu Q; Su Y; Wang X; Xuan Z; Wang Y; Xu F; Ge C
    J Ethnopharmacol; 2023 Mar; 303():115965. PubMed ID: 36460296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.